PRESS RELEASE: Bridge Pharmaceuticals Announces Executive Management Selections

Bridge Pharmaceuticals Announces Executive Management Selections: Appointment of CEO, Selection of CSO and Promotion of CFO

GAITHERSBURG, Md. -- Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer. Bridge is a global leader in preclinical contract research services with facilities in the US and China. "I am proud and excited to lead Bridge as globalization dawns in preclinical drug development," said Mr. Oakley. "Just a few years ago, dramatically lowering research costs through globalization was only talked about. Today it is the new reality and an immense opportunity for our company. Bridge is poised for tremendous growth in demand for our services both in the US and China."

 

Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience. Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development. Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

Mr. Patrik Jeanmonod assumes leadership as the Chief Financial Officer after holding the position of Vice President of Finance at Bridge. Patrik joined Bridge in June of 2006 and was responsible for leading the Finance and IT groups through growth and acquisition of Gene Logic Laboratories Preclinical Services Division. In addition, Patrik has been instrumental in leading the process of integrating our US and China Finance and IT operations into one global business.

Dr. Ronald Marler has been selected as Chief Scientific Officer and will continue as a member of the Board of Directors. Dr. Marler has over 27 years of experience in the pharmaceutical research and product development industries including holding positions of Division Vice-President, North America Toxicology Services at Covance Laboratories and Vice-President of Global Drug Safety at Marion Merrell Dow. In his new role as CSO at Bridge, Dr. Marler will be responsible for the scientific affairs of the company as well as advisor to the CEO and the Board.

Bridge Overview

Bridge Pharmaceuticals, Inc. is one of the first preclinical contract research organization (CRO) to provide US-level drug development services in both Asia and the US. Bridge is headquartered in the United States with laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing cost-effective, FDA compliant drug development services for pharmaceutical, biotech and government clients. Bridge's current capabilities in preclinical drug development include GLP compliant toxicology, safety pharmacology, pathology and bioanalytical services. For more information, visit http://www.bridgecro.com.

Contact: Bridge Pharmaceuticals, Inc. In USA Marisa Pawlewicz, 240-364-6249 [email protected] or In China Tina Huang, 86-10-8072-8800 [email protected]

Suggested Articles

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.